Literature DB >> 24162922

Medical treatment of hypertension in patients with heart failure with preserved ejection fraction.

Richard G Kiel1, Prakash Deedwania.   

Abstract

Heart failure with preserved ejection fraction (HFPEF) has become an increasingly common problem, accounting for as many as half of all diagnoses of heart failure. Hypertension has been shown to be a major risk factor for the development of HPEF, and the treatment of hypertension is key to both preventing the development of HFPEF as well as mitigating its impact on our health care system. While numerous studies have looked at using various classes of antihypertensive medications to treat HFPEF, there are still no well validated treatment strategies which have shown a significant mortality benefit. As a result, when choosing an antihypertensive medication to treat or prevent HFPEF, it is important to tailor the choice of antihypertensive medication to an individual patient's specific symptoms and comorbidities.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24162922     DOI: 10.1007/s11886-013-0428-5

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  16 in total

Review 1.  A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension.

Authors:  Arnfried U Klingbeil; Markus Schneider; Peter Martus; Franz H Messerli; Roland E Schmieder
Journal:  Am J Med       Date:  2003-07       Impact factor: 4.965

2.  Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects.

Authors:  Paolo Verdecchia; Fabio Angeli; Roberto Gattobigio; Mariagrazia Sardone; Sergio Pede; Gian Paolo Reboldi
Journal:  Am J Hypertens       Date:  2006-05       Impact factor: 2.689

3.  Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance.

Authors:  J F Setaro; B L Zaret; D S Schulman; H R Black; R Soufer
Journal:  Am J Cardiol       Date:  1990-10-15       Impact factor: 2.778

4.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

5.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

Authors:  Marcus D Flather; Marcelo C Shibata; Andrew J S Coats; Dirk J Van Veldhuisen; Aleksandr Parkhomenko; Joszef Borbola; Alain Cohen-Solal; Dan Dumitrascu; Roberto Ferrari; Philippe Lechat; Jordi Soler-Soler; Luigi Tavazzi; Lenka Spinarova; Jiri Toman; Michael Böhm; Stefan D Anker; Simon G Thompson; Philip A Poole-Wilson
Journal:  Eur Heart J       Date:  2005-01-09       Impact factor: 29.983

6.  Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.

Authors:  Bertram Pitt; Nathaniel Reichek; Roland Willenbrock; Faiez Zannad; Robert A Phillips; Barbara Roniker; Jay Kleiman; Scott Krause; Daniel Burns; Gordon H Williams
Journal:  Circulation       Date:  2003-09-29       Impact factor: 29.690

7.  Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects.

Authors:  R O Bonow; V Dilsizian; D R Rosing; B J Maron; S L Bacharach; M V Green
Journal:  Circulation       Date:  1985-10       Impact factor: 29.690

8.  Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.

Authors:  Yutaka Takeda; Tatsuya Fukutomi; Shogo Suzuki; Koji Yamamoto; Masaki Ogata; Hiroaki Kondo; Masato Sugiura; Junsho Shigeyama; Makoto Itoh
Journal:  Am J Cardiol       Date:  2004-08-15       Impact factor: 2.778

9.  Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.

Authors:  Peter M Okin; Richard B Devereux; Sverker Jern; Sverre E Kjeldsen; Stevo Julius; Markku S Nieminen; Steven Snapinn; Katherine E Harris; Peter Aurup; Jonathan M Edelman; Bjorn Dahlof
Journal:  Circulation       Date:  2003-07-28       Impact factor: 29.690

10.  Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry.

Authors:  Adrian F Hernandez; Bradley G Hammill; Christopher M O'Connor; Kevin A Schulman; Lesley H Curtis; Gregg C Fonarow
Journal:  J Am Coll Cardiol       Date:  2009-01-13       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.